Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy

International Journal of Radiation Oncology Biology Physics

Volumn 79, Issue 2, 2011, Pages 363-370

  Martinez, Alvaro A ^a   Gonzalez, Jose ^a   Ye, Hong ^a   Ghilezan, Mihai ^a   Shetty, Sugandh ^a   Kernen, Kenneth ^a   Gustafson, Gary ^a   Krauss, Daniel ^a   Vicini, Frank ^a   Kestin, Larry ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

Dose escalation; High dose rate brachytherapy; Prostate cancer; Radiation

Indexed keywords

BED-LEVEL; BIOCHEMICAL FAILURE; CLINICAL FAILURE; DISTANT METASTASIS; DOSE ESCALATION; DOSE FRACTIONATION; DOSE LEVELS; DOSE RESPONSE RELATIONSHIPS; EQUIVALENT DOSE; EXTERNAL BEAM RADIATION THERAPY; EXTERNAL BEAM RADIOTHERAPY; GLEASON SCORES; HAZARD RATIO; HIGH DOSE; HIGH DOSE RATE; HIGH-DOSE RATE BRACHYTHERAPY; LOCOREGIONAL CONTROL; LOW DOSE; MULTI VARIATE ANALYSIS; PRE-TREATMENT; PROSTATE CANCERS; PROSTATE SPECIFIC ANTIGEN; RADIATION DOSE;

DISEASES; MULTIVARIANT ANALYSIS; ONCOLOGY; PATHOLOGY; PATIENT MONITORING; QUALITY ASSURANCE;

RADIOTHERAPY;

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; TREATMENT FAILURE;

ADULT; AGED; AGED, 80 AND OVER; ALPHA PARTICLES; BETA PARTICLES; BRACHYTHERAPY; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; FOLLOW-UP STUDIES; HUMANS; IRIDIUM RADIOISOTOPES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK;

EID: 78650804126     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.10.035     Document Type: Article

References (31)

1. D.P. Dearnaley, E. Hall, D. Lawrence, R.A. Huddart, R. Eeles, and C.M. Nutting Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects Br J Cancer 92 2005 488 498
2. A. Pollack, G.K. Zagars, G. Starkschall, J.A. Antolak, J.J. Lee, and E. Huang Prostate cancer radiation dose response: Results of the M.D. Anderson phase III randomized trial Int J Radiat Oncol Biol Phys 53 2002 1097 1105
3. W.U. Shipley, L.J. Verhey, J.E. Munzenrider, H.D. Suit, M.M. Urie, and P.L. McManus Advanced prostate cancer: The results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone Int J Radiat Oncol Biol Phys 32 1995 3 12
4. J.R. Sathya, I.R. Davis, J.A. Julian, Q. Guo, D. Daya, and I.S. Dayes Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate J Clin Oncol 23 2005 1192 1199
5. A.L. Zietman, M.L. DeSilvio, J.D. Slater, C.J. Rossi Jr., D.W. Miller, and J.A. Adams Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial JAMA 294 2005 1233 1239
6. D.J. Demanes, R.R. Rodriguez, L. Schour, D. Brandt, and G. Altieri High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results Int J Radiat Oncol Biol Phys 61 2005 1306 1316
7. R.M. Galalae, A. Martinez, T. Mate, C. Mitchell, G. Edmundson, and N. Nuernberg Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer Int J Radiat Oncol Biol Phys 58 2004 1048 1055
8. A.A. Martinez, L.L. Kestin, J.S. Stromberg, J.A. Gonzalez, M. Wallace, and G.S. Gustafson Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: The William Beaumont phase II dose-escalating trial Int J Radiat Oncol Biol Phys 47 2000 343 352
9. A.A. Martinez, G. Gustafson, J. Gonzalez, E. Armour, C. Mitchell, and G. Edmundson Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer Int J Radiat Oncol Biol Phys 53 2002 316 327
10. A.A. Martinez, D. Yan, D. Lockman, D. Brabbins, K. Kota, M. Sharpe, D. Jaffray, F. Vicini, and J. Wong Improvement in dose escalation using the process of adaptive radiotherapy combined with 3-D conformal or intensity modulated beams for prostate cancer Int J Radiat Oncol Biol Phys 50 5 2001 1226 1234
11. O. Cahlon, M.J. Zelefski, A. Shippy, H. Chan, Z. Fuks, Y. Yamada, M. Hunt, S. Greenstein, and H. Amols Ultra-high dose (86.4 GY) IMRT for localized prostate cancer: toxicity and biochemical outcomes Int J Radiat Oncol Biol Phys 71 2 2008 330 337
12. G.K. Edmundson, N. Rizzo, and M. Teahan Concurrent treatment planning for outpatient high dose rate prostate template implants Int J Radiat Oncol Biol Phys 27 1993 1215 1223
13. G.K. Edmundson, D. Yan, and A. Martinez Intraoperative optimization of needle placement and dwell times for conformal prostate brachytherapy Int J Radiat Oncol Biol Phys 33 1995 1257 1264
14. A.A. Martinez, J. Gonzalez, W. Spencer, G. Gustafson, L. Kestin, D. Kearney, and F. Vicini Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors J of Urol vol 169 2003 974 980
15. D.J. Brenner, A.A. Martinez, G.K. Edmundson, C. Mitchell, H.D. Thames, and E.P. Armour Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue Int J Radiat Oncol Biol Phys 52 2002 6 13
16. G.M. Duchesne, and L.J. Peters What is the alpha/beta ratio for prostate cancer? Rationale for hypofractionated high-dose-rate brachytherapy Int J Radiat Oncol Biol Phys 44 1999 747 748
17. J.F. Fowler The radiobiolo Gy of prostate cancer including new aspects of fractionated radiotherapy Acta Oncol 44 2005 265 276
18. N.S. Goldstein, A. Martinez, and F. Vicini The histolo Gy of radiation therapy effect on prostate adenocarcinoma as assessed by needle biopsy after brachytherapy boost: Correlation with biochemical failure Am J Clin Pathol 110 1998 765 775
19. American Joint Committee on Cancer Prostate O.H. Beahrs, D.E. Henson, R.V.P. Hutter, B.J. Kennedy, AJCC cancer staging manual 4th edition 1992 Lippincott-Raven Philadelphia 181 186
20. M. Roach, G. Hanks, and H. Thames Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference Int J Radiat Oncol Biol Phys 65 2006 965 974
21. Ghilezan M, Park S, Ye H, et al. A modified Phoenix biochemical failure definition to account for PSA bounce phenomenon for prostate patients treated with brachytherapy. Int J Radiat Oncol Biol Phys 75(3):S311.
22. E. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
23. D.R. Cox Regression models and life-tables J R Stat Soc B 34 1972 187 220
24. N.N. Stone, L. Potters, and B. Davis Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score of 7-10 prostate cancer treated with permanent prostate brachytherapy Int J Radiat Oncol Biol Phys 73 2 2009 341 346
25. D. Jaffray, J. Siewerdsen, J. Wong, and A.A. Martinez Flat panel cone-beam computed tomography for image guided radiation therapy Int J Radiat Oncol Biol Phys 53 5 2002 1337 1349
26. D. Yan, F. Vicini, and J. Wong Adaptive radiation therapy Phys Med Biol 42 1997 123 132
27. M. Bolla, D. Gonzalez, P. Warde, J.B. Dubois, R.O. Mirimanoff, and G. Storme Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin N Engl J Med 337 1997 295 300
28. D.A. Kuban, S.L. Tucker, L. Dong, G. Starkschall, E.H. Huang, M.R. Cheung, A.K. Lee, and A. Pollack Long-term results of the MD Anderson randomized dose-escalation trial for prostate cancer Int J Radiat Oncol Biol Phys 70 1 2008 67 74
29. Z. Fuks, S.A. Leibel, K.E. Wallner, C.B. Begg, W.R. Fair, and L.L. Anderson The effect of local control on metastatic dissemination in carcinoma of the prostate: Long-term results in patients treated with 125I implantation Int J Radiat Oncol Biol Phys 21 1991 537 547
30. C.R. Pound, A.W. Partin, M.A. Eisenberger, D.W. Chan, J.D. Pearson, and P.C. Walsh Natural history of progression after PSA elevation following radical prostatectomy JAMA 281 1999 1591 1597
31. S.J. Freedland, E.B. Humphreys, L.A. Mangold, M. Eisenberger, F.J. Dorey, and P.C. Walsh Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy JAMA 294 2005 433 439 (Pubitemid 41124175)